These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 34560556)

  • 1. A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery.
    Shadbad MA; Asadzadeh Z; Derakhshani A; Hosseinkhani N; Mokhtarzadeh A; Baghbanzadeh A; Hajiasgharzadeh K; Brunetti O; Argentiero A; Racanelli V; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Nov; 143():112213. PubMed ID: 34560556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study.
    Shadbad MA; Ghorbaninezhad F; Hassanian H; Ahangar NK; Hosseinkhani N; Derakhshani A; Shekari N; Brunetti O; Silvestris N; Baradaran B
    Front Med (Lausanne); 2022; 9():1027758. PubMed ID: 36388933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.
    Ashizawa M; Okayama H; Ishigame T; Thar Min AK; Saito K; Ujiie D; Murakami Y; Kikuchi T; Nakayama Y; Noda M; Tada T; Endo H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
    Mol Cancer Res; 2019 Jun; 17(6):1403-1413. PubMed ID: 30872332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E; Rasmi Y; Baradaran B
    J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1.
    Azarbarzin S; Hosseinpour-Feizi MA; Banan Khojasteh SM; Baradaran B; Safaralizadeh R
    Life Sci; 2021 Feb; 267():118939. PubMed ID: 33359245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
    Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
    Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
    Chen YL; Wang GX; Lin BA; Huang JS
    Cell Biol Int; 2020 May; 44(5):1224-1236. PubMed ID: 32068322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miREIA - an immunoassay method in assessment of microRNA levels in tumor tissue-pilot study. The impact of miR-93-5p, miR-142-5p and IFNγ on PD-L1 level in colorectal cancer.
    Dawidowicz M; Kula A; Mielcarska S; Kiczmer P; Gołąbek K; Ostrowska Z; Waniczek D; Świętochowska E
    Acta Biochim Pol; 2021 Apr; 68(2):247-254. PubMed ID: 33826281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.
    Zhao L; Yu H; Yi S; Peng X; Su P; Xiao Z; Liu R; Tang A; Li X; Liu F; Shen S
    Oncotarget; 2016 Jul; 7(29):45370-45384. PubMed ID: 27248318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer.
    Kang E; Jung SC; Nam SK; Park Y; Seo SH; Park KU; Oh HK; Kim DW; Kang SB; Lee HS
    Sci Rep; 2022 Feb; 12(1):2295. PubMed ID: 35145164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA
    Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
    Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
    Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
    Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.
    Cai L; Chen A; Tang D
    Immunology; 2024 Oct; 173(2):209-226. PubMed ID: 38517066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer.
    Dastmalchi N; Azarbarzin S; Safaralizadeh R; Khojasteh SMB; Shadbad MA; Amini M; Baghbanzadeh A; Asl ER; Baghbani E; Lotfinejad P; Baradaran B
    Med Oncol; 2021 Nov; 39(1):9. PubMed ID: 34761351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S; Wang K; Huang X; Zhao Z; Zhao Z
    Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.